Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

19 May 2020 07:00

RNS Number : 2669N
Ideagen PLC
19 May 2020
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

19 May 2020

 

Ideagen PLC

("Ideagen," "the Company" or the "Group'')

 

Pre-Close Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, is pleased to provide an update on trading for the year ended 30 April 2020 and the outlook entering the new financial year.

 

The publication of the Company's full year results for the period to 30 April 2020 will be slightly later than normal this year and are expected to be published on or around the 22nd September 2020. This follows discussions with the Company's advisers and auditors and is due to the prevailing circumstances surrounding the COVID-19 pandemic and the practical difficulties that it will impose upon the audit process.

 

 

Trading Statement

 

The Board is pleased to report that trading for the year to 30 April 2020 was strong and results are expected to be in line with market expectations. This represents the Group's eleventh consecutive year of revenue and adjusted EBITDA* growth.

 

The Group expects to report revenue up 21% at approximately ÂŁ56.6million as compared to ÂŁ46.7million in the previous financial year. Adjusted EBITDA* is expected to be up 29% to approximately ÂŁ18.5m on an IFRS16 basis and, on a like-for-like IAS17 basis, up 22% to approximately ÂŁ17.5m.

 

The Board considers Annual Recurring Revenue (ARR) as its primary growth metric and the driver for long term value. ARR recognised during the year is expected to be ÂŁ43.1m, representing an increase to 76% of total revenues from 67% the previous year. The ARR book as at 30 April 2020 was up 34% to approximately ÂŁ48.7 million from ÂŁ36.4 million, arising from both strong organic growth of approximately 19% on the previous year and acquired ARR from three acquisitions made within the year.

 

It is particularly pleasing to note that the organic growth was driven by 458 new customer logo wins across verticals such as Healthcare, Life Sciences, Financial Services and US Government, with new customers including the US Federal Reserve, SSE, Emirates and Corbus Pharmaceuticals. Investment appetite from new customers in sectors that have been more intensely impacted by the pandemic, including the Aviation and Manufacturing sectors, has as expected been slower. Reflecting the importance of the Group's software to our customers, there has been no material impact on the Group's existing customer relationships or the ARR book as a result of COVID-19.

 

Cash generated by operations was ahead of expectations at over 95% of adjusted EBITDA*, resulting in a gross cash balance of ÂŁ8.2m and gross bank borrowings of ÂŁ25.0m at the period end. Net bank debt at the year end of ÂŁ16.8m was lower than anticipated and comfortably within banking covenants. As a result, the Group remains in a robust financial position.

 

Outlook

 

 

The Board reiterates the guidance it provided on 7 April 2020. Ideagen's software is considered business critical by our customers and this, together with a strong ARR book, gives the Board confidence that the ÂŁ15m run rate revenue from the final quarter of previous financial year will continue as expected. The Group has also implemented a prudent cost reduction programme that has generated approximately ÂŁ4m in annual savings.

 

In light of this, the Group believes it has the right financial model to meet market expectations for the current year and continues to intend to pay a dividend in respect of the financial year in line with its progressive dividend policy. The Group expects to declare this dividend at its full year results in line with its normal practice.

 

 

 

 

Ben Dorks, Chief Executive commented:

 

"We are pleased to report that despite the impact of COVID-19, the Group has continued to perform well in delivering yet another year of quality earnings growth underpinned by strong cash generation. The Group has now successfully transitioned to primarily a recurring revenue model and has quickly responded to the new and challenging business backdrop we all face. I would like to thank all our employees who have displayed great resilience and fortitude during these difficult times".

 

 

*Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and other exceptional items.

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

 

Ben Dorks, Chief Executive

 

Graeme Spenceley, Finance Director

 

 

 

 

 

 

finnCap Limited

 

020 7220 0500

Henrik Persson, James Thompson (NOMAD)

 

Alice Lane (ECM)

 

 

 

 

Canaccord Genuity Limited

 

020 7523 8000

Simon Bridges, Richard Andrews

 

 

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 6,000 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTVVLFFBELLBBZ
Date   Source Headline
26th Jan 201610:43 amRNSDirector/PDMR Shareholding
26th Jan 20167:00 amRNSInterim Results
13th Jan 20161:41 pmRNSHolding(s) in Company
22nd Dec 20157:00 amRNSExercise of Options and Total Voting Rights
11th Dec 20159:53 amRNSHolding(s) in Company
25th Nov 20151:42 pmRNSHolding(s) in Company
24th Nov 20157:00 amRNSHolding(s) in Company
19th Nov 20157:00 amRNSTrading Update
5th Nov 201511:23 amRNSChange of Registered Office Address
29th Oct 20153:59 pmRNSResult of AGM
20th Oct 20157:00 amRNSExercise of Options
7th Oct 20157:00 amRNSNotice of AGM
23rd Sep 20158:15 amRNSEnlighten product wins GRC Innovation Award
3rd Sep 20157:00 amRNSNew Contract Extensions worth £1m
10th Aug 20157:00 amRNSExercise of Options and Total Voting Rights
31st Jul 201511:54 amRNSDirector Dealing
23rd Jul 20157:00 amRNSGrant of Share Options
22nd Jul 20157:00 amRNSFinal Results
9th Jul 20157:00 amRNSNotice of Results
30th Jun 20159:19 amRNSShares Magazine Investor Event
3rd Jun 201511:25 amRNSHolding(s) in Company
21st May 20157:00 amRNSG-Cloud Award and New Contract Win
14th May 20157:00 amRNSPre-Close Trading Update
7th May 20157:00 amRNSExercise of Options and Total Voting Rights
30th Apr 201510:26 amRNSHolding(s) in Company
23rd Apr 201511:55 amRNSHolding(s) in Company
20th Apr 20152:53 pmRNSReplacement Director Dealing & Total Voting Rights
20th Apr 20157:00 amRNSDirector Dealing & Total Voting Rights
15th Apr 201511:25 amRNSHolding(s) in Company
11th Mar 201511:23 amRNSHolding(s) in Company
6th Mar 201512:57 pmRNSHolding(s) in Company
25th Feb 20157:00 amRNSExercise of Options and Total Voting Rights
24th Feb 20157:00 amRNSNew Aviation Contract Wins worth £1m
29th Jan 20157:00 amRNSInterim Results
20th Jan 20153:41 pmRNSHolding(s) in Company
16th Jan 201512:44 pmRNSHolding(s) in Company
16th Jan 201512:42 pmRNSHolding(s) in Company
13th Jan 20151:04 pmRNSCompletion of Acquisition of Gael Limited
9th Jan 201511:55 amRNSHolding(s) in Company
7th Jan 201512:56 pmRNSResult of General Meeting
18th Dec 20147:00 amRNSAcquisition, Placing and Notice of General Meeting
13th Nov 20147:00 amRNSTrading update and Notice of Results
5th Nov 20148:30 amRNSIdeagen selected by NuGen
31st Oct 20141:47 pmRNSResult of AGM
9th Oct 20147:00 amRNSNotice of 2014 Annual General Meeting ("AGM")
2nd Oct 20147:00 amRNSContract Win and Trading Update
4th Aug 20147:00 amRNSIssue of Equity
22nd Jul 20147:00 amRNSFinal Results
10th Jul 20147:00 amRNSNotice of Results
25th Jun 20147:01 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.